Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Vorinostat | HDAC | Misc | 1.2388 | -0.3848 | 0.2821 | 0.1116 | 1.7685 | 1.7699 | 0.99365 |
MDA-MB-231 | Luminespib | HSP90 | Misc | 0.0057951 | -0.1782 | 0.6452 | 0.2269 | 3.8625 | 0.006261 | 0.99815 |
MDA-MB-231 | A-1210477 | Mcl-1 | Misc | Inf | 0.9569 | 0.0519 | 0.0034 | 0.0000 | Inf | -8.5977e-09 |
MDA-MB-231 | Olaparib | PARP | Misc | 14.6165 | 0.6179 | 0.0581 | 0.0050 | 0.9419 | 46.7541 | 0.98031 |
MDA-MB-231 | Bleomycin | Radiation | Misc | 6.333 | 0.4365 | 0.1320 | 0.0030 | 1.0810 | 2.968 | 0.97684 |
MDA-MB-231 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.9254 | 0.0073 | -0.0008 | 0.0000 | Inf | 0.28623 |
MDA-MB-231 | Alpelisib | PI3Ka | PI3K/mTOR | 48.2918 | 0.6904 | 0.0895 | 0.0045 | 0.4504 | 553.5356 | 0.61498 |
MDA-MB-231 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 2.1958 | 0.0709 | 0.2540 | 0.0294 | 0.4838 | 21.2709 | 0.9085 |
MDA-MB-231 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.8508 | 0.0154 | 0.0050 | 0.6946 | 20.4646 | 0.68698 |
MDA-MB-231 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0251 | -0.0262 | 0.3856 | 0.0478 | 1.0287 | 0.023885 | 0.98855 |
MDA-MB-231 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.7110 | 0.2246 | -0.0006 | 0.0000 | Inf | 0.54965 |
MDA-MB-231 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.021834 | 0.1013 | 0.4860 | 0.0253 | 1.0516 | 0.015209 | 0.98917 |
MDA-MB-231 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.8544 | 0.0105 | 0.0068 | 4.2838 | 3.8501 | 0.8794 |
MDA-MB-231 | Buparlisib | pan PI3K | PI3K/mTOR | 1.5103 | -0.2351 | 0.2751 | 0.0596 | 1.9855 | 1.8969 | 0.98328 |
MDA-MB-231 | Pictilisib | pan PI3K | PI3K/mTOR | 5.3159 | 0.3053 | 0.2062 | 0.0120 | 0.3649 | 107.9707 | 0.87205 |
MDA-MB-231 | Ceritinib | ALK | RTK | 0.86565 | -0.3326 | 0.3444 | 0.1014 | 1.9065 | 1.1609 | 0.99581 |
MDA-MB-231 | Neratinib | EGFR/HER2 | RTK | 1.4329 | -0.0957 | 0.1056 | 0.0516 | 1.6284 | 2.8124 | 0.99527 |
MDA-MB-231 | Tivantinib | MET | RTK | 0.41694 | -0.0845 | 0.3330 | 0.1029 | 2.2640 | 0.43275 | 0.99134 |
MDA-MB-231 | Cediranib | VEGFR/cKIT | RTK | 5.0964 | -0.3620 | 0.1160 | 0.0659 | 2.7537 | 7.595 | 0.99835 |
MDA-MB-231 | Cabozantinib | VEGFR2/MET | RTK | 4.8325 | 0.0749 | 0.1413 | 0.0336 | 1.2384 | 11.7338 | 0.95871 |
SK-BR-3 | Abemaciclib | CDK4/6 | Cell cycle | 0.035311 | 0.1432 | 0.5363 | 0.0387 | 0.6381 | 0.016543 | 0.96857 |
SK-BR-3 | Palbociclib | CDK4/6 | Cell cycle | 0.17601 | 0.3503 | 0.2849 | 0.0218 | 0.9678 | 0.038204 | 0.97912 |
SK-BR-3 | AZD7762 | CHK1/2 | Cell cycle | 0.02013 | -0.4509 | 0.9023 | 0.2866 | 3.0174 | 0.024464 | 0.99546 |
SK-BR-3 | Volasertib | PLK | Cell cycle | 0.0054419 | -0.3494 | 0.7044 | 0.2799 | 4.1140 | 0.0060939 | 0.9976 |
SK-BR-3 | Dinaciclib | pan CDK | Cell cycle | 0.0068129 | -0.6209 | 0.8362 | 0.3009 | 3.4320 | 0.008573 | 0.99807 |